Clinical Trial Update: A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384) [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing tenofovir alone versus in combination with pegylated interferon alfa-2b for chronic hepatitis B has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis B | Phase 4 | Status: WITHDRAWN